相关实验视频
Updated: Sep 16, 2025

07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
536
我如何治疗儿科肺栓塞?
Ayesha Zia1, Neil A Goldenberg2, Madhvi Rajpurkar3
1University of Texas Southwestern Medical Center, Dallas, Texas, United States.
Blood
|July 11, 2025
概括
儿童肺栓塞 (PE) 正在增加,特别是在青少年中. 风险预测,抗凝试验和了解长期影响方面的进展正在改善管理,尽管问题仍然存在.
科学领域:
- 儿科血液学 儿科血液学
- 心血管医学 心血管医学
- 临床研究 临床研究
背景情况:
- 静脉血栓塞栓症 (VTE) 影响200名住院儿童中的1名.
- 肺栓塞 (PE) 的诊断,一种严重的VTE形式,在过去二十年中增加了200%,特别是在青少年中.
- 儿科PE的管理是高度可变的,需要更新的临床指南.
研究的目的:
- 审查过去十年儿科PE管理和研究的最新进展.
- 突出临床实践的转变,包括PE响应小组和多学科决策.
- 讨论抗凝治疗的进展,了解PE后综合征以及未来的研究需求.
主要方法:
- 在过去10年内对儿科PE发表的研究进行了审查.
- 对儿童和青少年抗凝血药物的临床试验分析.
- 检查关于后PE综合征和管理策略的研究.
主要成果:
- 实施儿科PE响应小组和重症病例的多学科方法.
- 完成了儿科抗凝药的临床试验,并正在研究最佳治疗持续时间.
- 了解和评估后PE综合征的进展.
结论:
- 在儿科PE诊断和管理方面取得了重大进展.
- 持续的研究对于解决剩余的问题和完善治疗方案至关重要.
- 多学科护理和基于证据的指导方针对于改善儿科PE的结果至关重要.
相关概念视频
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
46
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
46
Pulmonary Embolism III: Nursing Management
44
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
44
Pulmonary Embolism I: Introduction
50
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
50
Venous Thrombosis III: Interprofessional Care
26
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
26
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
227
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
227
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
258
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
258

